Dr Elias Jabbour speaks to ecancer in online video interview about the management and treatment of patients with acute lymphoblastic leukaemia (ALL) during the COVID-19 pandemic.

He emphasises that patient care and life-saving treatments should not be compromised during the pandemic as this population of patients are highly curable.

Dr Jabbour outlines some examples of how treatment practices have been amended to minimise the risk of COVID-19 for patients with ALL.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content